Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 8, 2002, Pages 2704-2707

  Delmas, G ^a   Park, S ^a   Chen, Z W ^a   Tan, F ^a   Kashiwazaki, R ^a   Zarif, L ^a   Perlin, D S ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DERIVATIVE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B-DEOXYCHOLATE; ANTIFUNGAL AGENT; DEOXYCHOLIC ACID; DRUG DERIVATIVE; DRUG VEHICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLOSIS; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; KIDNEY; LIVER; LUNG; NONHUMAN; ORGANISM COLONY; PRIORITY JOURNAL; REDUCTION; SURVIVAL; TREATMENT OUTCOME; TREATMENT PLANNING; ANIMAL; BAGG ALBINO MOUSE; DRUG COMBINATION; FEMALE; METABOLISM; MICROBIOLOGY; MOUSE; TISSUE DISTRIBUTION; VEHICLES;

AMPHOTERICIN B; ANIMAL; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; DEOXYCHOLIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; KIDNEY; LIVER; LUNG; MICE; MICE, INBRED BALB C; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION; VEHICLES; ANIMALS; DRUG COMBINATIONS;

EID: 0035992021     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.8.2704-2707.2002     Document Type: Article

References (17)

1. Invasive aspergillosis
2. Treatment of invasive aspergillosis with itraconazole
3. Amphotericin B: 30 Years of clinical experience
4. Development of liposomal amphotericin B formulation
5. Lipid-based amphotericin B: A review of the last 10 years of use
6. Lipid formulations of amphotericin B: Recent progress and future directions
7. Aspergillus fumigatus and aspergillosis
8. A comparative review of conventional and lipid formulations of amphotericin B
9. Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis
10. Amphotericin B nephrotoxicity: The adverse consequences of altered membrane properties
11. Tissue distribution of amphotericin B after multiple oral dosing of amphotericin B cochleate (CAMB) in a murine model
12. Practice guidelines for diseases caused by Aspergillus
13. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis
14. New targets and delivery systems for antifungal therapy
15. Lipid formulations of amphotericin B: Clinical efficacy and toxicities
16. Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model
17. Cochleates: New lipid-based drug delivery system